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OBJECTIVE: MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression at the post-
transcriptional level. Some miRNAs, including let-7a and miR-195, have been described as tumor suppressors.
However, the roles of these microRNAs in breast cancer progression remain controversial. The aim of this study is
to evaluate miR-195 and let-7a expression as potential biomarkers of invasive breast cancer.
METHODS: In the present study, 200 individuals were separated into three groups: (i) 72 women constituting the
control group who were selected according to rigorous and well-established criteria; (ii) 56 patients with benign
breast tumors; and (iii) 72 patients with malignant breast cancers of different clinical stages. The miR-195 and
let-7a expression levels in serum were evaluated by real-time PCR. The results were assessed alone and in
combination, and the analysis included an estimation of sensitivity and specificity in ROC curves.
RESULTS: Compared with the benign and control groups, both microRNAs were downregulated in the mali-
gnant breast cancer patient group. Compared with the malignant group, the combination of both biomarkers
in the control and benign groups showed good sensitivity and specificity in the serum with AUCs of 0.75 and
0.72, respectively. The biomarker combination for the control group versus the malignant group exhibited a
better sensitivity and specificity than for the benign group versus the malignant group.
CONCLUSION: These findings support the evidence that the analysis of miR-195 and let-7a can be used as a non-
invasive biomarker for breast cancer detection.
KEYWORDS: Breast Cancer; Biomarkers; Tumor Suppressors; Early Detection; microRNAs.
’ INTRODUCTION
MicroRNAs (miRNAs) are small non-coding RNAs that
are approximately 22 nucleotides in length, and these RNAs
regulate gene expression at the posttranscriptional level (1).
These molecules are conserved across species and are deregu-
lated in several diseases, including cancer (2–4). Evidence has
shown that miRNAs are located on fragile sites of the genome
and/or cancer-associated regions and act either as oncogenes
or tumor suppressors (5).
The tumor suppressor miRNAs of the let-7 family regulate
important oncogenes, such as c-MYC, H-RAS, and HMGA2,
and several cell cycle regulators (6–8). Let-7a is the most
conserved of the let-7 family members, exhibiting high
sequence similarity between many organisms from Caenor-
habditis elegans to humans (7). Let-7a is frequently down-
regulated in several types of cancers (8). Let-7a is regulated
by p53 and its homologues, demonstrating the tumor
suppressive properties of these regulators (9). In addition,
let-7a is involved in glucose metabolism (10) and angio-
genic mechanisms (11).
In breast cancer cells, let-7 processing is affected by LIN28,
which binds to the terminal loops of let-7 precursors,
leading to the inhibition of its processing and the induction
of uridylation (12). A recent study reported that LIN28
decreased Myc expression after MAPK signaling inhibition,
which consequently led to let-7 induction and the suppression
of breast cancer bone metastasis in animal models (13).
Raf kinase inhibitory protein (RKIP) can regulate LIN28
and, consequently, let-7 in breast cancer (13). In addition,
other forms of let-7 regulation have been shown in breast
cancer. For example, let-7 regulation can occur via miRNA
regulation by other miRNAs, such as the interaction with
miR-107, which downregulates let-7 during tumor pro-
gression (14).DOI: 10.6061/clinics/2018/e184
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Another important miRNA tumor suppressor, miR-195, is
a member of the miR-15/16/195/424/497 family, which is
characterized by the same 30 untranslated region (30UTR)
binding seed sequence and similar bases AGCAGC near the
50 ends of mature miRNAs (15). The tumor suppressor func-
tion of miR-195 has been associated with the downstream
effectors of NF-kB, especially IKKa and TABP3, linking
inflammation to tumorigenesis (16). miR-195 downregula-
tion has been observed in several types of cancers and may
be associated with the copy number loss of a segment of
chromosome 17p13.1, as observed in ovarian serous carci-
noma (17). Moreover, epigenetic alterations, namely, promo-
ter CpG methylation, have also been associated with miR195
downregulation in gastric cancer, with consequent deregula-
tion of its direct target CDK6 (18).
In hepatocellular carcinoma, miR-195 induces G1 arrest by
affecting cell cycle regulators (19) and blocking the G(1)/S
transition by repressing Rb-E2F signaling through the
targeting of CCND1, CDK6, and E2F3 (20). This microRNA
has been described as a downregulator of WEE1, the major
gate keeper at the G2 cell cycle checkpoint, and affects the
migration and invasion of melanoma cells (21). In addition,
another miR-195 target, TARBP2, affects cell proliferation
and apoptosis and seems to discriminate between adenomas
and carcinomas (22). In breast cancer, miR-195 downregula-
tion is affected by the methylation status of the CpG island
(23). Using luciferase assays, Li et al. (23) showed that the
RAF-1 and CCND1 transcripts were direct targets of miR-195
in breast cancer. The authors of this study also performed a
Western blot analysis of both targets in several breast cancer
cell lines to validate the regulation of these targets after miR-
195 transfection.
A recent study by Heneghan et al. (24) demonstrated
that miR-195 expression could differentiate breast cancer
from other cancers. Indeed, the upregulation of miR-195
and let-7a showed a significant correlation with clinico-
pathological variables, such as nodal status and estrogen
receptor status (25). Moreover, the downregulation of
miR-195 expression was observed in an athymic mouse model
of breast cancer (26).
The possibility of miRNA detection in cell-free forms,
such as exosomes, together with specific properties, such as
tissue specificity and stability, indicates that miRNAs are
important biomarkers (27). In this study, we aimed to assess
whether the miR-195 and let-7a expression levels in the
serum samples of breast cancer patients could be used as
biomarkers of breast carcinogenesis. The selection of these
microRNAs is based on the existing contradictory results in
the literature.
’ MATERIALS AND METHODS
Patient selection
The current prospective controlled exploratory study was
approved by the local Ethical Research Committee (protocol
#272/2009). The patients were selected according to their
clinical features and pathological biopsy data. They were
categorized into three groups (Table 1). Group I was con-
sidered a control group and included women between 40
and 69 years of age, with Gail scores o1.66 and normal
radiological examinations (28). Group II, the benign group,
constituted women with mammary biopsies and radiological
alterations (BI-RADS IV) or clinical pathological discordance
in which the pathological findings showed the absence of
cancer. In this group, lesions were considered benign and low
risk, with the exclusion of atypical and higher-risk alterations.
Finally, group III comprised randomly selected patients with
invasive ductal carcinoma, and the inclusion criteria were
associated with the patients’ consent with the study and
the RNA quality of the samples. The AJCC 7th classification
(TNM) was used for clinical staging (29).
Blood sample collection
Blood was collected in BD Vacutainer SST II Advance
(367955) collection tubes, and serum separation was perfor-
med within 2 hours of collection. Samples were then stored
at -80oC until use. Venous blood samples were collected from
patients prior to any surgery/biopsy or chemotherapy or
radiotherapy treatment.
In parallel, pathological data were analyzed from FFPE
material with immunohistochemistry markers. Estrogen and
progesterone receptors were considered positive after detec-
tion of nuclear expression X1%, regardless of the staining
intensity. Her2 was considered positive with a 3+ score if
30% of the cells were stained. A percentage of 10-30 was
considered a 2+ score, by FISH or DISH immunofluo-
rescence. Ki67 was also measured; however, due to the
low number of cases, the luminal A and B-Her2-negative
molecular subtypes were grouped. Molecular classifica-
tion by immunohistochemistry was performed according
to Goldhirsch et al. (30).
RNA isolation and real-time PCR (qRT-PCR) assay
The RNA isolation protocol using MiRNeasy (Qiagen,
Hilden, Germany) was used for serum samples. Quantification
was performed using a nanodrop ND-1000 spectrophotometer
(NanoDrop Products, Wilmington, DE, USA).
For real-time PCR, 10 ng of total RNAwas used to perform
reverse transcriptase reactions using Taqman miRNA Assays
Table 1 - Clinicopathological group characteristics.*
Group I - Healthy Group II – Benign Group III Neoplastic
n=72 n=56 n=72
Female Female Female
Asymptomatic Appropriate clinical and radiological correlation Appropriate clinical and radiological correlation
Normal mammography Open biopsy Open biopsy
Low cancer risk (Gail o 1.66) Benign lesion at microscopy Invasive ductal carcinoma
Absence of familial history Lesion with absence of pathological cancer risk Adequate TNM evaluation
Unilateral tumor
Absence of previous treatment
Absence of second primary tumor
* Serum evaluation.
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(Life Technologies, Inc., Carlsbad, CA, USA), according to
the manufacturer ’s instructions. All real-time PCR reac-
tions were run as technical triplicates in a 7900 HT Fast
Real-time PCR System (Applied Biosystems USA, Foster
City, CA, USA).
Data analysis
The analysis procedures were performed in the R environ-
ment (version 3.1.1) (31). The normalization step was perfor-
med according to the 2-DDCt method (32). Cycle threshold (Ct)
values from the selected miRNA targets were subtracted
from the Ct values of endogenous small non-coding RNA
control RNU6 (Figure 1) (Control miRNA Assay, Applied
Biosystems). A subsequent DDCt value was calculated for
the malignant tumors using the lower expression values
of the control or benign DCt values. Expression values are
represented as the DDCt value on a log2 scale. Statistical
analysis was performed using one-way ANOVA with a
significance level of pp0.05. To assess the sensitivity and
specificity of each biomarker, ROC curve analysis was used.
Analysis of the combination of biomarkers was performed
using a general logistic model (glm). ROC analysis was
performed using the ROCR package (33).
’ RESULTS
Clinical data
The features of each group are summarized in Tables 1
and 2. Group I comprised 72 healthy women, with a median
age of 51.4 years (40-68) and Gail score of 1.16 (0.93-1.60).
No malignancy focus was observed in this group, and the
BI-RADS I, II, and III frequencies in this group were 47.2%,
48.6%, and 4.2%, respectively.
The benign group, Group II, comprised 56 women, with
a median age of 49.8 years (27-79) and Gail score of 1.9 (0.93
to 6.91). All lesions in this group presented the radiological
characteristics of BI-RADS IV, which was determined by
mammography, mammary ultrasonography, and magnetic
resonance for 44.6%, 53.6%, and 1.8% of the patients, respec-
tively. The major pathological findings were typical ductal
hyperplasia (n=20), sclerosing adenosis (n=11), fibroade-
noma (n=11), simple adenosis (n=3), benign phyllodes tumor
(n=2), papilloma (n=2), and apocrine metaplasia (n=2). These
categories represented 91.1% of the findings.
Group III, the malignant group, comprised 72 breast
cancer patients with a median age of 54 years (28-81) and a
median tumor size of 2.6 cm (1-15 cm). Only 8.3% of the
patients in group III had a diagnosis of metastasis. Only one
patient presented with lobular carcinoma, which was obser-
ved after histological revision, and the patient was not
excluded. The patient presented levels of expression that
were similar to those of the other patients in the group.
The main characteristics of group III were TNM II and III
(72.2%), TNM-T T1/T2 (68.0%), TNM-N N0/N1 (73.6%),
and luminal A/B Her2-negative, according to immunohisto-
chemical analysis.
Table 2 - Pathological features of breast cancer patients (Group 3).
Variable Category Number %












Disease Local 28 38.9
Extension* Regional 38 52.8
Metastasis 6 8.3
Estrogen Positive 56 77.8
receptor Negative 16 22.2
Progesterone Positive 45 62.5
receptor Negative 27 37.5
Her2 Positive 20 27.8
Negative 52 72.2
Molecular Luminal A/B Her2 - 44 61.1
Subtypes (30) Luminal B Her2 + 13 18.1
Triple negative 8 11.1
Her 2 7 9.7
All - 72 100.0
* Local=tumors N0, regional=tumors N+, metastasis=tumors M1.
Figure 1 - Relative quantification values of miR-16 and U6 used to normalize the control and breast cancer samples.
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Data analysis
The expression levels of miRNAs, namely, miR-195 and
let7a, were assessed by qRT-PCR, and a comparison between
the serum expression levels was performed for the control,
benign, and malignant groups (Figure 2). We observed down-
regulation in both let-7a (Figure 2-A) and miR-195 (Figure 2-B)
in the malignant group compared with the control and benign
groups. One-way ANOVA of these data showed p-values
of 0.0004 for let-7a and 0.006 for miR-195.
The combination of these biomarkers showed higher
values for sensitivity and specificity, with an AUC of 0.75
when the malignant breast cancer samples were compared
with the control samples (Figure 3-A) and with an AUC of
0.72 when the benign patients were compared with the mali-
gnant patients (Figure 3-B). ROC curve analysis of miR-195
and let-7a did not show good sensitivity or specificity (data
not shown).
’ DISCUSSION
In the present study, we showed that the combination of
the miR-195 and let-7a expression values presented good
sensitivity and specificity in the sera of the control and
benign groups compared with the serum of the malignant
group. Even though these miRNAs have been described in
a wide range of tumors, including breast cancer, the pre-
sent study is innovative because it uses well-defined control
groups, which exclude analysis bias. This study presents
innovative biomarkers for the evaluation of breast cancer.
Additionally, let-7a was found in exosomes, reinforcing the
possibility of its detection in serum (27).
There is growing evidence that exosomal miRNAs that
are secreted by donor cells are taken up by recipient or even
cancer cells and that these miRNAs can be used as bio-
markers (34). Exosomal miRNAs have pleiotropic roles in
modulating many physiological and pathological processes,
including cancer metastasis (35). There is evidence that tumor-
derived exosomes facilitate tumor-stroma interactions and pro-
mote the formation of a supportive metastatic niche in distant
organs, due in part to easier access to the vascular system (35).
Henegan et al. (24) studied the expression of circulating
miRNAs in several tumor types (breast, colon, prostate, kidney,
and melanoma) compared to that in normal individuals and
found that miR-195 was upregulated only in breast cancer,
suggesting that miR-195 could be a potential breast cancer
biomarker, in association with let-7a. This study consisted of
Figure 2 - Relative quantification values are represented as log2 of the DDCt value, which was calculated using RNU6 as a housekeeping
gene and was adjusted with the lower expression values of the control or benign DCt values for the malignant tumors. (A) let-7a and
(B) miR-195 expression in the sera of the control, benign, and malignant breast cancer groups.
Figure 3 - Receiver operating characteristic (ROC) curves after combining let-7a miR-195 expression values using a general logistic
model. (A) ROC curve of the control group versus the malignant group; (B) ROC curve of the benign versus malignant groups.
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83 women, and used a normal control group; however, the
specific features of the control group were not described.
The control groups were not described or well-defined and
there was no description of the methods for the tissue
analysis. This fact represents a bias, especially because
both miRNAs are downregulated in a wide range of tumor
types.
Interestingly, Sempere et al. (36) reported the downregu-
lation of let-7a in breast cancer. Moreover, miR-195 was
found to be downregulated in the circulation of a breast
cancer animal model (26), in concordance with the present
study. After a comparison of studies, discordance in the data,
which can be explained by differences in the control group
selection process and the number of patients who make up
this group, becomes apparent. In the present study, a higher
number of normal individuals, together with rigorous and
well-established criteria, was used (Table 1).
In addition, reduced miR-195 expression in cancer pro-
gression has presented a correlation with poor overall
survival in other cancer types, such as tongue squamous
cell carcinoma (37) and multiform glioblastoma (38). Recen-
tly, Wang et al. (39) has described the role of miR-195 in
metastasis, where reduced levels were associated with
angiogenesis and worse recurrence-free survival in hepa-
tocellular carcinoma cells. The authors suggest that miR-
195 affects the expression of the proangiogenic factor
VEGF and the pro-metastatic factors VAV2 and CDC42.
MiR-195 was negatively correlated with extracellular
matrix (ECM) accumulation, reinforcing its role in metas-
tasis (40). Recently, miR-195 was highlighted as a potentially
predictive biomarker for the lymph node metastasis of gastric
cancer (41).
The findings of the present study are consistent with a vast
amount of evidence pointing to let-7a and miR-195 as tumor
suppressors, whose downregulation and better sensitivity
and specificity in combination provide evidence for their
utilization as non-invasive biomarkers in breast cancer pro-
gression. Currently there are no good circulating biomarkers
related to breast cancer. The known biomarkers, namely,
CEA, CA15-3, and CA 27-29, present limited sensitivity and
specificity and are not used for diagnostic or follow-up
purposes in clinical practice (42). On the other hand, the
combination of let-7a and miR-195 expression has been pre-
viously described as a potential circulating biomarker (25),
and our findings indicate that this combination may be useful
as a standard assessment, with an AUC of 0.72. Considering
the absence of a better non-invasive biomarker in the literature
and considering the lower costs of qPCR (approximately US$
30.00), their efficacy should be considered, and further studies
are necessary to confirm these findings.
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